Clicky

Rain Therapeutics Inc.(RAIN)

Description: Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is RAIN-32, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing RAIN-32 that has completed Phase II clinical trial in liposarcoma, Phase I clinical trial in solid tumors, and Phase II clinical trial in intimal sarcoma, as well as RAD52 for tumors, including breast, ovarian, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.


Keywords: Medicine Cancer Clinical Medicine Solid Tumors Tumor Prostate Cancer Antineoplastic Drugs Targeted Therapy Tyrosine Kinase Receptors Bemcentinib

Home Page: www.rainthera.com

RAIN Technical Analysis

8000 Jarvis Avenue
Newark, CA 94560
United States
Phone: 510 953 5559


Officers

Name Title
Mr. Avanish Vellanki M.B.A. Co-Founder, CEO & Chairman
Dr. Robert C. Doebele M.D., Ph.D. Co-Founder, Member of Scientific Advisory Board, Pres & Chief Scientific Officer
Dr. Richard P. Bryce Exec. VP & Chief Medical Officer
Mr. Nelson D. Cabatuan Sr. VP of Fin. & Admin.
Ms. Theresa O'Connell M.S. Director of Corp. Devel. & Operations
Ms. Vijaya Tirunagaru Ph.D. Sr. VP & Head of Research
Mr. Lucio Tozzi Sr. VP of Clinical Operations
Ms. Buenaflor Nicolas M.P.H. VP, Head Global Drug Safety & Pharmacovigilance
Dr. Nora Ku M.D. MD & VP of Clinical Devel.
Dr. Mehdi Paborji Ph.D. Sr. VP of Technical Operations

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 3.0259
Price-to-Sales TTM: 0
IPO Date: 2021-04-23
Fiscal Year End: December
Full Time Employees: 44
Back to stocks